Business Context and Reporting Period
Company: Arvinas, Inc. (ARVN)
Filing Type: Form 8-K (Current Report)
Date: December 10, 2024
Context: The filing discloses preliminary clinical data from the Phase 1b portion of the TACTIVE-U sub-study for vepdegestrant, an investigational oral PROTAC ER degrader co-developed with Pfizer, Inc. The data pertains to patients with locally advanced or metastatic ER+/HER2- breast cancer.
Key Financial Metrics
This Form 8-K is a disclosure of clinical trial results and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Clinical Findings
The filing reports preliminary results from 16 patients in the Phase 1b sub-study (data cut-off: August 30, 2024) evaluating vepdegestrant in combination with abemaciclib:
- Clinical Benefit Rate (CBR): 62.5% observed across all CBR-eligible patients (10/16), including 62.5% in patients with mutant ESR1 and 62.5% in patients with wild-type ESR1.
- Objective Response Rate (ORR): 26.7% overall (4/15 evaluable patients), 37.5% in mutant ESR1 patients, and 14% in wild-type ESR1 patients.
- Safety Profile: The combination demonstrated a tolerable safety profile with no dose-limiting toxicities and no Grade 4 or 5 treatment-emergent adverse events (TEAEs). Common TEAEs included diarrhea, nausea, and fatigue.
- Pharmacokinetics: No significant drug-drug interaction was observed between vepdegestrant and abemaciclib.
Outlook, Management Commentary, and Risks
Outlook: The findings support the ongoing Phase 2 portion of the TACTIVE-U clinical trial, which is evaluating full-dose abemaciclib (150mg BID) in combination with vepdegestrant (200mg QD) in post-CDK4/6 advanced breast cancer.
Management Commentary: The data will be presented in a poster at the 2024 San Antonio Breast Cancer Symposium (SABCS) on December 12, 2024.
Risks/Contingencies: The filing notes that the information is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings except as expressly set forth.
Key Facts for Investor Verification
- Verify the full presentation of data at the 2024 San Antonio Breast Cancer Symposium (SABCS) on December 12, 2024.
- Monitor the initiation and progress of the Phase 2 portion of the TACTIVE-U trial.
- Review the long-term safety data as the study continues, noting that 5 patients remained on treatment as of the August 30, 2024 cut-off.
- Confirm the specific definitions of CBR and ORR used in the study relative to industry standards.